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Abstract
Objectives To investigate the proportion of original studies included in
systematic reviews and meta-analyses on the diagnostic accuracy of
screening tools for depression that appropriately exclude patients who
already have a diagnosis of or are receiving treatment for depression
and to determine whether these systematic reviews and meta-analyses
evaluate possible bias from the inclusion of such patients.
Design Systematic review.
Data sources Medline, PsycINFO, CINAHL, Embase, ISI, SCOPUS,
and Cochrane databases were searched from 1 January 2005 to 29
October 2009.
Eligibility criteria for selecting studies Systematic reviews and
meta-analyses in any language that reported on the diagnostic accuracy
of screening tools for depression.
Results Only eight of 197 (4%) unique publications from 17 systematic
reviews and meta-analyses specifically excluded patients who already
had a diagnosis of or were receiving treatment for depression. No
systematic reviews or meta-analyses commented on possible bias from
the inclusion of such patients, even though 10 reviews used quality
assessment tools with items to rate risk of bias from composition of the
sample of patients.
Conclusions Studies of the accuracy of screening tools for depression
rarely exclude patients who already have a diagnosis of or are receiving
treatment for depression, a potential bias that is not evaluated in
systematic reviews and meta-analyses. This could result in inflated
estimates of accuracy on which clinical practice and preventive care
guidelines are often based, a problem that takes on greater importance
as the rate of diagnosed and treated depression in the population
increases.
Introduction
Depressionisacommonanddisablingcondition,
1andimproving
care has been prioritised. Routine screening for depression is
one solution that has been proposed. Depression screening
involves the use of screening tools to identify patients who
might have depression but who are not seeking treatment for
symptoms and whose depression is not otherwise recognised
by their physicians so that they can be further assessed and, if
appropriate, treated.
2 3 Screening for depression has been
recommended in several medical settings, including
cardiovascular care,
4 perinatal care,
5-7 oncological care,
8 and
primary care,
9 although no clinical trial has found better
depression outcomes for screened versus unscreened patients
when the same treatment and care resources are potentially
available to both groups.
10 11 Screening for depression can
identify patients with depression who might otherwise go
undetected,butitcanalsoleadtomisdiagnosis,theidentification
of patients as being depressed who are not, and overdiagnosis,
which occurs when some patients with mild conditions are
identified as depressed and exposed to the risk of labelling and
treatment,evenwhentheconditionmightnotcausemeasurable
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Research
RESEARCHmorbidity or mortality. Recently, a report from the National
Institute for Health and Clinical Excellence (NICE)
11 noted a
lack of evidence for benefit from depression screening and,
rather than routine screening, recommended case identification
strategies to identify depression among high risk groups of
patientsorpatientsotherwiseidentifiedbyphysiciansaspossibly
having depression.
A great deal of research has been conducted to determine the
diagnostic accuracy of depression screening tests in different
clinicalsettings.Basedondatafromsuchstudies,expertpanels
have considered the risks and benefits of screening and issued
recommendationstoscreenfordepressioninvarioussettings.
9 11
Diagnostic or screening tests, however, are useful only to the
extent that they distinguish between disordered and
non-disordered states that are not otherwise obvious to
clinicians
12 and if they are accurate across the spectrum of
patients who will be assessed in clinical practice.
12-18
Theterm“spectrumeffect”hasbeenusedtodescribevariations
in test performance that sometimes occur across subgroups of
patientsthatdifferindemographicorclinicalfeatures.Spectrum
effectsraisequestionsaboutthegeneralisabilityofstudyresults
tospecificpopulationsofpatientsthatmightdifferinimportant
ways from study samples.
19 The term “spectrum bias” is related
and also describes situations in which the accuracy of a test is
heterogeneous across subgroups of patients. Spectrum bias is
said to be present when a study samples preferentially from
certain portions of the patient spectrum but provides a global
estimate of accuracy that could misrepresent what would be
experienced in actual practice.
12-19 Estimates of diagnostic
accuracy that are based on case-control designs and whose
samples include only obvious cases and healthy controls, for
instance, have been shown to substantially overestimate
diagnostic accuracy.
13 14 18
Self reported depression questionnaires are used for various
purposes (such as screening for unidentified cases, tracking
severity of symptoms, detecting relapse). For the purpose of
screening, which involves the identification of cases not
previously recognised, if individuals who already have a
diagnosis of depression are not specifically excluded from
studiesassessingthediagnosticaccuracyofdepressionscreening
tools, examined cohorts will have a greater prevalence and
severityofdepressionthanifonlyindividualswithoutclinically
recognised depression were screened. Not excluding patients
who already have a diagnosis would, in turn, lead to
determinations of screening accuracy and new case yield that
are inflated compared with what would be achieved if the
instrument were used to screen patients in clinical practice.
12-18
Systematic reviews and meta-analyses are highly cited and are
prioritised in grading evidence for practice guidelines.
20 21 If
studiesofthediagnosticaccuracyofdepressionscreeningtools
that include patients who already have a diagnosis or are
receiving treatment are included in systematic reviews and
meta-analyses without adjustment for potential bias, these
reviews could provide misleading accuracy estimates, thereby
misleading calculations of risk-benefit by expert panels and,
thus, clinicians.
We evaluated the proportion of studies included in systematic
reviews and meta-analyses of the diagnostic accuracy of
depression screening tools that excluded patients who already
had a diagnosis of or were receiving treatment for depression.
We also assessed whether authors of systematic reviews and
meta-analyses noted the possibility of spectrum bias from the
inclusion of such patients in the original research studies they
reviewed. We hypothesised that few studies of depression
screeningtoolswouldexcludesuchpatientsandthatsystematic
reviews and meta-analyses would not consider spectrum bias
from their inclusion.
Methods
Selection of systematic reviews and
meta-analyses
We searched Medline, PsycINFO, CINAHL, Embase, ISI,
SCOPUS, and Cochrane databases from 1 January 2005 to 29
October 2009 for systematic reviews and meta-analyses of the
diagnosticaccuracyofdepressionscreeningtools.Werestricted
thesearchtothisperiodtoobtainrecentsystematicreviewsand
meta-analysesthatreflectrelativelycurrentpractice.Thesearch
terms used were ((systematic review OR meta-analysis) AND
(screening OR sensitivity OR specificity) AND depression).
Eligiblearticlesincludedsystematicreviewsandmeta-analyses
inanylanguagepublishedinfinalformorontheinternetbefore
final publication that reviewed the accuracy of screening tools
for depression compared with a diagnosis of depression.
Depression screening tools included any self report measure
usedtoattempttoidentifypatientswithdepression.Weincluded
systematic reviews and meta-analyses that reviewed diagnostic
accuracy and other psychometric characteristics of depression
questionnaires (such as validity and reliability) but extracted
data only on diagnostic accuracy. We excluded systematic
reviews and meta-analyses that compared scores only on self
report screening tools with classifications of depression based
on cut offs from other self report screening tools but not a
diagnosisofdepression.Twoinvestigatorsreviewedsystematic
reviewsandmeta-analysesforeligibilityindependently.Ifeither
reviewer deemed a systematic review or meta-analysis
potentially eligible based on a review of the title and abstract,
we carried out a full text review of the systematic review or
meta-analysis. Any disagreement between reviewers after full
text review was resolved by consensus after consultation with
an independent third reviewer. Chance corrected agreement
between reviewers was assessed with Cohen’s κ.
Data extraction
Two investigators independently extracted and entered on a
standardisedspreadsheetdataitemsfromthesystematicreviews
andmeta-analyses,aswellasfromtheoriginalstudiesincluded
in the reviews, with discrepancies resolved by consensus. For
eachsystematicreviewormeta-analysis,theyrecordedwhether
or not original studies mentioned possible bias because of the
inclusion of patients who already had a diagnosis of or were
receivingtreatmentfordepression.Investigatorsalsodetermined
whetherornoteachsystematicreviewormeta-analysisincluded
an assessment of the quality of included diagnostic accuracy
studies.Ifso,theyrecordedthetoolthatwasusedtodothisand
whether or not the tool included an evaluation of the risk of
spectrum bias. Investigators also recorded the impact factor of
the journal in which each systematic review or meta-analysis
was published, using the impact factor for the year of
publication.
22 In addition, they reviewed the introduction and
discussionsectionsandrecordedthedescribedpurposeforwhich
accuracy of the screening tool was being assessed (such as
screening or identification of new cases, monitoring progress
of treatment, detection of relapse).
Original diagnostic accuracy studies included in the systematic
reviews and meta-analyses were classified as having excluded
patients who already had a diagnosis of or were receiving
treatment for depression if the authors of the study specifically
indicated this in the exclusion criteria. If studies did not
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classified as having included them.
For each systematic review or meta-analysis, and overall, we
determinedthenumberofuniquepublicationsonthediagnostic
accuracy of depression screening tools, as well as the number
of unique cohorts of patients. We assessed the number of
publications and the number of cohorts because, in some cases,
there were multiple publications from the same cohort. This
occurred, for instance, when different publications reported
resultsfromdifferentscreeningtoolsorcriterionstandardswith
the same group of patients, when one or more publications
reported on a subset of the sample from another publication, or
when the same patients were assessed at different time points
(such as during pregnancy and after delivery). Identification of
different publications from the same cohort was done by cross
referencing authors and coauthors, characteristics of patients,
andcountriesinwhichtheresearchwasconducted.Verification
wasdonebycomparinginformationinthepublications.Cohort
statuswascodedconservativelyinthatpublicationsthatseemed
to be from the same cohort were coded as such, even if this
could not be confirmed with 100% certainty.
We did not publish or register a review protocol for this study.
All methods were determined a priori with the exception of
reviewingtheintroductionanddiscussionsectionstorecordthe
described purpose for which the accuracy of depression
screening tool was being assessed. This additional step was
added to the study methods after data extraction and tabulation
of results to clarify whether the intention of the included
systematic reviews and meta-analyses was to assess diagnostic
accuracy for identification of new cases versus other possible
uses of depression symptom questionnaires.
Results
Search results
The electronic database search yielded 1216 unique titles and
abstracts for review. Of these, 1160 were excluded after review
of titles and abstracts because they did not report results from
a systematic review or meta-analysis or because they reported
data from a systematic review or meta-analysis that was not
relatedtothediagnosticaccuracyofadepressionscreeningtool.
Of the 56 articles that underwent full text review, we excluded
39, leaving 17 eligible systematic reviews and meta-analyses
(figure⇓). Chance corrected agreement on inclusion and
exclusion decisions between reviewers, as assessed with the
Cohen’s κ, was 0.95.
Table1showsthecharacteristicsofselectedsystematicreviews
and meta-analyses⇓. Of the 17 systematic reviews and
meta-analyses included, 10 were systematic reviews,
23-32 and
seven were meta-analyses.
33-39 The systematic reviews and
meta-analyses included between two and 63 original studies
and were published in a wide range of journals in terms of
impact factor. Two meta-analyses assessed the nine item
depressionscaleofthepatienthealthquestionnaire(PHQ-9)
33 39;
one systematic review
23 and two meta-analyses
37 38 evaluated
thegeriatricdepressionscale;sevensystematicreviews
24 26 27 29-32
and one meta-analysis
36 assessed depression screening tools,
generally, in defined medical populations; two systematic
reviewsassessedspecificscreeningtools,otherthanthepatient
health questionnaire or geriatric depression scale, in defined
patient populations
25 28; and two meta-analyses assessed brief
screening tools (for example, fewer than five items) in primary
care
34 and palliative care.
35 All 17 systematic reviews and
meta-analyses described the purpose of the review as related to
determining diagnostic accuracy for new case detection by
screening, and none discussed how their results might apply to
other uses of depression screening tools (such as monitoring
progress of treatment, detection of relapse).
Inclusion or exclusion of patients who already
had a diagnosis or were receiving treatment
The 17 systematic reviews and meta-analyses included a total
of 197 unique publications on the diagnostic accuracy of
screeningtoolsfordepressionin170uniquecohortsofpatients.
Thediagnosticaccuracystudiesexaminedmorethan25different
screening tools in a wide range of patients (see appendix 1 on
bmj.com).Onlyeightof197uniquepublications(4%)andeight
of 170 cohorts (5%) specifically excluded patients who already
had a diagnosis of or were receiving treatment for depression
(see appendix 1). As shown in table 1, 11
23 26 27 30-33 35 37-39 of the
17systematicreviewsormeta-analysesdidnotexamineasingle
cohort of patients that specifically excluded those who already
had a diagnosis of or were receiving treatment for depression.
Table 2⇓ shows that only four
40-43 of the eight studies that
excluded such patients reported the number of patients who
were excluded because of pre-existing mental health treatment.
The proportion of patients excluded for this reason was 22% in
a Veteran’s Affairs primary care setting in the United States
(publishedin2004)
43;10%ina2003studyofpatientsingeneral
practicefromNewZealand
42;2%ina2004studyofpostpartum
women from Turkey
40; and 0.2% in a 1996 study of postpartum
women from Sweden.
41
Treatment of spectrum bias in systematic
reviews and meta-analyses
As shown in table 1, 13
23-25 27 30-36 38 39 of the 17 systematic
reviews and meta-analyses conducted some form of quality
assessmentofincludedstudies,includingtwometa-analyses
36 39
thatusedthequalityassessmentfordiagnosticaccuracystudies
(QUADAS) tool
44; one systematic review
27 that used the
diagnosticteststudiesevaluationtool
45;onemeta-analysis
34that
used the Newcastle-Ottawa scale
46; two systematic reviews
30 32
that used methods developed by the US Preventive Services
Task Force (USPSTF)
47 48; one systematic review
31 that based
quality review on guidelines from the American Academy of
Neurology
49; one systematic review
25 that evaluated quality
items based on a system from the York Centre for Reviews and
Dissemination
50; one systematic review
24 that used a study
specific tool based on criteria identified by the Cochrane
Methods Working Group on Systematic Review of Screening
and Diagnostic Tests
51; one meta-analysis
35 that based quality
ratings on a published article by Pai et al
52; and one systematic
review
23andtwometa-analyses
33 38thatusedadhocprocedures,
such as extracting data on one to two items related to study
quality.
Of these, 10 systematic reviews or meta-analyses
24 25 27 30-32 34-36 39
used quality assessment methods that included an assessment
of spectrum bias. The authors of one of these systematic
reviews
24 noted study limitations from the lack of non-white
patients, and the authors of another
32 reported that younger
children were poorly represented in studies of children and
adolescents.Theauthorsofonemeta-analysisreportedthathalf
of studies reviewed did not include representative samples but
did not provide a rationale for this conclusion.
36 The authors of
another noted the possibility of a “disease progression bias” in
one study of patients after stroke and indicated that none of the
other11studiesreviewedhadlimitationsrelatedtocomposition
of patients.
39 In one systematic review, one of four included
studies was downgraded because of the description of the
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2011;343:d4825 doi: 10.1136/bmj.d4825 Page 3 of 11
RESEARCHsample, but an explanation was not provided.
27 The authors of
the five other systematic reviews or meta-analyses that used
quality assessment methods that included an assessment of
spectrum bias did not comment specifically on quality ratings
related to possible spectrum bias.
21 26 27 30 31
Overall, none of the 17 systematic reviews or meta-analyses
commented on possible spectrum bias from the inclusion in
studies of patients who already had a diagnosis of or were
receiving treatment for depression.
Discussion
Wefoundthatlessthan5%ofstudiesonthediagnosticaccuracy
of depression screening tools appropriately excluded patients
who already had a diagnosis of or were receiving treatment for
depression.Theimportanceofthisfindingrelatestothepotential
effect on assessments of the accuracy of depression screening
instrumentsandthenumberofnewcasestheywilluncoverand,
therefore, on their utility in clinical practice. The diagnostic
accuracy of a screening test is often considered a fixed
characteristic of a test, but it can vary substantially in
populations with different clinical features.
16 Studies that have
examined accuracy of diagnostic tests consistently show that
increased prevalence or severity of disease in the cohort of
patients being examined inflates the reported sensitivity of the
test being assessed.
14 If the accuracy of screening tools for
depression was studied in a group of patients, some of whom
had already received a diagnosis for the condition, the
assessments would be biased by the inclusion of individuals
with a greater prevalence and severity of depression than if the
instruments were used in clinical practice to screen patients
without clinically recognised depression. This would, in turn,
lead to inflated, and potentially misleading, estimates of
accuracy on which clinical practice and preventive care
guidelines are generally based.
Potential magnitude of problem
Thepotentialmagnitudeofthisproblemgrowsastheprevalence
of already diagnosed and treated depression in the population
increases.
53 54 Estimates of the prevalence of depression in
primarycarerangefrom5%to13%,including6%to9%among
adults aged 55 or older.
55 Rates are somewhat higher in patients
with chronic physical illness.
1 Among adults aged 35 and older
intheUS,ratesofantidepressantuseincreasedfrom8%to14%
from 1996 to 2005, with a third to a half of prescriptions
specifically for psychiatric problems.
53 Rates of prescriptions
for antidepressants might be even higher among patients with
chronicphysicaldisease.BasedonprovincialdatafromOntario,
Canada, for instance, the rate of antidepressant prescriptions
within six months of an acute myocardial infarction doubled
from 8% in 1993 to 16% in 2002 among patients aged 65 and
older.
56 In a more recent cohort of more than 1200 outpatients
with stable cardiovascular disease, just under 20% were treated
with an antidepressant at the time of enrolment in the study.
57 58
In addition to patients who receive treatment with
antidepressants, a relatively small percentage of people receive
psychotherapy for depression without drug treatment,
59 and
some people are recognised by their physicians as depressed
but choose not to undergo treatment.
Arecentmeta-analysisfoundthatgeneralpractitionerscorrectly
identify about 50% of patients with depression without the
assistance of a screening tool.
60 Dichotomising a doctor’s
identification or non-identification of depressive disorders,
however, could underestimate the degree to which they
recognise depression. A study of over 700 patients in primary
care from the US and the Netherlands, for instance, found that
complete disagreement between physicians’ assessments and a
diagnostic interview for depression was much less common
thanisoftenthought.
61Inthatstudy,only27%offalsenegative
casesbasedonphysicianassessmentsweretruefalsenegatives.
In most cases of false negatives, physicians recognised
symptoms of depression but underestimated severity compared
withthediagnosticinterview(40%)orgaveanotherpsychiatric
diagnosis(33%).Thus,inmanysettings,asubstantialproportion
of depressed patients are recognised as depressed without
screening,eitherbecausetheyseektreatmentfortheirdepression
or because a healthcare professional otherwise recognises their
symptoms. Based on reported rates of prescriptions for
antidepressantsandestimatesofphysicians’abilitytorecognise
depression, it could be that as many as half or more of patients
who are detected as cases in studies assessing the diagnostic
accuracy of screening tools would not even be screened in
clinical practice.
Data are not available that would allow a precise calculation of
the degree by which studies that fail to exclude patients who
already have a diagnosis of or are receiving treatment for
depression might overestimate diagnostic accuracy and the
number of new patients who would be identified through
depression screening. Two reviews, however, have reported
that studies of other types of diagnostic tests that have used
case-control designs
13 or case-control designs that compared
severely affected patients and healthy controls
18 substantially
overestimatediagnosticaccuracy(relativediagnosticoddsratios
3.0
13 and 4.9,
18 respectively).
Evenarelativelysmallincreaseinreporteddiagnosticaccuracy
resulting from the inclusion of patients who already have a
diagnosisorarereceivingtreatmentwouldresultinasubstantial
overestimateofthepositivepredictivevalueandnewcaseyield
from depression screening compared with what would be
expected in clinical practice. A systematic review of the
diagnostic accuracy of depression screening tools in primary
care found a median sensitivity of 85% and median specificity
of 74%.
62 Based on this, in a primary care setting with a
prevalence rate of 10%,
55 32% of all patients would screen
positive for depression, of whom 27% would be true positive
cases, equivalent to 9% of all patients screened. If existing
studies overestimated the sensitivity by even 10% because of
the inclusion of patients with a diagnosis or being treated
(relative diagnostic odds ratio 1.9), and it is conservatively
assumed that physicians recognise 50% of depressed patients
without screening, the rate of screening with positive results
would decrease only slightly, from 32% to 27%. Only 14% of
these, however, would be true positives, and, overall, less than
4% of patients screened would be newly identified cases of
depression (see appendix 2 on bmj.com).
We know of only one study, which was not included in any of
the systematic reviews or meta-analyses that we reviewed, that
assessed the yield of screening for depression with and without
excluding patients with psychiatric disorders already treated
with psychotropic drugs.
63 In that study of 113 women with
breast cancer, the true positive rate of screening for depression
fell from 21% to 7% after exclusion of patients who were
already receiving treatment for depression before screening.
Our results should be considered in the context of studies that
haveassessedwhetherscreeningfordepressionbenefitspatients.
There are at least 11 trials in primary care,
10 as well as trials in
perinatal care,
64 65 and cancer care,
66 that have tested whether
screening and referral for depression treatment improves
depression outcomes, and all have had negative results.
Reflecting this, the US Preventive Services Task Force
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RESEARCHrecommendsscreeningfordepressiononlywhenitissupported
by integrated staff assisted depression management
programmes.
9 To our knowledge, only one published research
study has documented an attempt to screen and provide
collaborative care, as recommended by the task force, in a
clinicalsetting.
67Inthatstudy,fromtheNetherlands,1687high
risk patients were invited to enrol in a screening trial, 780
participated, and 71 cases of major depression were detected.
Ofthe71patientsidentified,36werealreadyreceivingtreatment
for depression and 18 additional patients refused treatment or
didnotattendtheirscheduledappointment.Thus,only17people
of 1687 potentially screened started treatment for depression.
Strengths and limitations of review
One possible limitation of the current study is that we searched
for systematic reviews and meta-analyses, rather than for
original studies, and there are probably many original studies
on the diagnostic accuracy of depression screening tools that
werenotincluded.Ourpurpose,however,wastoassesswhether
original studies appropriately excluded patients who already
had a diagnosis or were receiving treatment and to determine
whethersystematicreviewsandmeta-analysesreflectedpotential
bias from the failure to do this, which required a review of
reviews.Itisunlikelythatincludingadditionalstudiesthatwere
not listed in recent systematic reviews or meta-analyses would
have substantively altered the results.
Another potential limitation is that the proportion of patients
who already had a diagnosis of or were receiving treatment for
depressionwhowereinappropriatelyincludedinthediagnostic
accuracy studies reviewed is unknown. Only four of the studies
that excluded such patients reported the proportion excluded
for this reason, and this varied widely depending on the setting
and the time period of the study. It was less than 2% in studies
that collected data from 10 years ago in Turkey
40 and more than
15 years ago in Sweden,
41 but about 10% in a 2003 study of
patients in general practice from New Zealand
42 and just over
20% in a 2004 study of primary care patients treated in a US
Veteran’s Affairs setting.
43 In addition, the small number and
substantial heterogeneity of studies that excluded patients who
already had a diagnosis or were receiving treatment did not
allow for an assessment of the effect of inclusion and exclusion
decisions on diagnostic accuracy estimates. On the other hand,
numerous studies have found that the inclusion of established
casesamongexaminedcohortsconsistentlyinflatesassessments
of the accuracy of a diagnostic test,
14 and it is likely that this
would also be the case in studies of depression screening tools.
Conclusions and policy implications
The importance of our findings relates to the use of depression
questionnaires for screening, a procedure conducted to identify
previouslyunrecognisedcases.
2 3Inclinicalpractice,depression
questionnaires are sometimes used for purposes other than
screening, including monitoring the severity of symptoms in
patients who already have a diagnosis of depression and
assessing patients for recurrence of symptoms while they are
being treated. The introduction and discussion sections of the
17 systematic reviews and meta-analyses we reviewed indicate
that all were intended to assess the diagnostic accuracy and
utility of depression questionnaires for the purpose of
screening—that is, for identification of new cases. None
discussed how findings might apply to other possible uses for
the questionnaires (such as monitoring progress of treatment or
detection of relapse). In addition, the recommendations that
have been issued by expert panels regarding depression
screening in various settings discuss the use of screening
instruments as a means of identifying new cases.
Screeningfordepressionissomewhatdifferentfrommanyother
types of screening in that a history or interview might not
necessarily be part of the evaluation before a screening tool is
administered. To illustrate, the US Preventive Services Task
Forcerecommendsscreeningforcervicalcancerinwomenwho
havebeensexuallyactiveandhaveacervix.
68Ontheotherhand,
such screening is not recommended for women older than 65
orforwomenwhohaverecentlyhadanormalresultonasmear
test.Thisapproachtoscreeningispredicatedonsome“filtering”
to determine the appropriate individuals or groups to be
screened. On the other hand, the task force’s recommendations
regarding depression screening
9 focus on issues in healthcare
systems, such as the availability of staff assisted depression
care, rather than on any upstream evaluation of patients before
screening. In clinical settings, screening tools for depression
might be routinely administered to all patients in the waiting
room of a hospital, physician’s office, or clinic, as has been
recommended by expert panels.
4 Regardless of whether these
screening tools are used with or without upstream “filtering” in
clinical practice, accurate determinations of test characteristics
that reflect the ability to detect previously unrecognised cases
can be obtained only if this upstream “filtering” is done in
studies to exclude patients who already have a diagnosis of
depression. Our findings show that this is rarely done, and, as
a result, existing evidence on the accuracy and case yield of
depressionscreeningtoolscouldsubstantiallyoverestimatetheir
utility in clinical practice. Well designed studies that exclude
patients who already have a diagnosis of or are receiving
treatment for depression are needed to generate realistic
determinations of the accuracy of depression screening tools in
clinical settings to inform decisions about risks and benefits
with screening.
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RESEARCHWhat is already known on this topic
The results of studies on the accuracy of screening tools for depression are routinely used by expert panels to make
decisions about the potential benefits of depression screening
What this study adds
Studies of the accuracy of screening tools for depression rarely exclude patients who already have a diagnosis or are
receiving treatment, a potential bias that is not evaluated in systematic reviews and meta-analyses
This can result in inflated accuracy and estimates of the yield of new cases on which clinical practice and preventive
care guidelines are often based, a problem that takes on greater importance as the rate of diagnosed and treated
depression in the population increases
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RESEARCHTables
Table 1| Systematic reviews (SR) and meta-analyses (MA) of diagnostic accuracy of depression screening tools
Inclusion or
exclusion of Quality
assessment
Methodofquality
assessment
Cohorts that
excluded
Cohorts
reviewed
Publications
reviewed
Review
type
Screening tool,
patients/setting
Journal
impact
factor* Study
diagnosedor
included diagnosed or treated
spectrum
bias†
treated
patients
patients
noted
No‡ Yes Based on criteria
from Cochrane
working group
1 (5.0%) 20 23 SR Depression screening
tools in perinatal care
NA Gaynes, 2005
24
No NA No 1 (10.0%) 10 10 SR HADS in patients with
cancer
NA Morse, 2006
28
No No Ad hoc§ 0 (0%) 37 42 MA GDS in elderly patients 3.9 Wancata, 2006
38
No No Ad hoc§ 0 (0%) 15 18 MA PHQ-9 in primary care and
hospital settings
2.9 Gilbody, 2007
33
No Yes Newcastle-Ottawa
scale
3 (30.0%) 10 12 MA Short (<5 items) screening
tools in primary care
patients
2.2 Mitchell, 2007
34
No Yes Based on AAN
review guidelines
0 (0%) 2 2 SR Depression screening
tools in acute myocardial
infarction patients
2.2 Thombs, 2007
31
No Yes QUADAS 0 (0%) 9 12 MA PHQ-9 in primary care and
hospital settings
2.1 Wittkampf,
2007
39
No Yes Based on Pai et
al
48
0 (0%) 10 10 MA 1-2 questions in cancer
and palliative care
4.8 Mitchell, 2008
35
No NA No 1 (12.5%) 8 8 SR Depression screening
tools in palliative care
2.7 Thekkumpurath,
2008
29
No Yes USPSTF 0 (0%) 11 11 SR Depression screening
tools in cardiovascular
care
31.7 Thombs, 2008
30
No No Ad hoc§ 0 (0%) 4 4 SR GDS in older adults or
veterans in outpatient
settings
1.2 Allen, 2009
23
No Yes Based on York
Centre for Reviews
and Dissemination
system
2 (5.7%) 35 37 SR EPDS in perinatal care 3.7 Gibson, 2009
25
No Yes QUADAS 4 (7.1%) 56 63 MA Depression screening
tools in perinatal care
6.9 Hewitt, 2009
36
No NA No 0 (0%) 4 4 SR Depression screening
tools in spinal cord injury
patients
1.4 Kalpakjian,
2009
26
No Yes Diagnostic test
studies evaluation
tool
0 (0%) 4 4 SR Depression screening
tools in patients with pain
episode
3.0 Mirkhil, 2009
27
No Yes USPSTF 0 (0%) 9 9 SR Depression screening
tools in children and
adolescents
4.7 Williams, 2009
32
No NA No 0 (0%) 12 13 MA GDS in older primary care
patients
3.8 Mitchell, 2010¶
37
AAN=American Academy of Neurology; EPDS=Edinburgh postnatal depression scale; GDS=geriatric depression scale; HADS=hospital anxiety and depression
scale; NA=not applicable; PHQ-9=patient health questionnaire-9; QUADAS=quality assessment for diagnostic accuracy studies; USPSTF=US Preventive Services
Task Force.
*Impact factor from year systematic review or meta-analysis was published.
†Includes quality items related to “representativeness” of samples.
‡In methods authors wrote “We excluded studies that included patients with a known current depressive illness (for whom a screen would not provide new
information).” Of 23 studies included in systematic review, however, 22 did not exclude patients who were already recognised as depressed or treated for depression.
Authors of review did not comment on inclusion or exclusion of such patients in results or discussion.
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RESEARCHTable 1 (continued)
Inclusion or
exclusion of
diagnosedor
treated
patients
noted
Quality
assessment
included
spectrum
bias†
Methodofquality
assessment
Cohorts that
excluded
diagnosed or
treated
patients
Cohorts
reviewed
Publications
reviewed
Review
type
Screening tool,
patients/setting
Journal
impact
factor* Study
§Reported extraction of one to two items related to study quality (for example, blinding).
¶Article was epublication ahead of print at time of our search and was subsequently published in 2010.
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RESEARCHTable 2| Cohorts of diagnostic accuracy studies that excluded patients who already had diagnosis of or were receiving treatment for
depression
Exclusion criterion No (%) excluded
Year(s) data
collected Population
Country of original
study Study (review/s included in)
Taking psychotropic drugs 47/476 (10%) NR General practice patients New Zealand Arroll, 2003
42 (Mitchell
34)
Receiving psychotropic drugs NR NR General practice patients New Zealand Arroll, 2005
69 (Mitchell
34)
Psychiatric treatment history 6/347 (2%) 2001 Postpartum women Turkey Aydin, 2004
40 (Gibson,
25 Hewitt
36)
Diagnosis of depression during current
pregnancy
NR NR Postpartum women US Beck, 2005
70(Hewitt
36)
Mental health appointment in chart
within past 6 months
762/3466 (22%) 2002-3 Veteran’s Affairs primary care
patients
US Corson, 2004
43 (Mitchell
34)
Currently prescribed antidepressant
medication
NR NR Cancer patients in palliative
care
UK Lloyd-Williams, 2000, 2001
71 72
(Morse,
28 Thekkumpurath
29)
Current diagnosis of and receiving
treatment for psychiatric disorder
NR 2003-4 Women6-8weekspostpartum Thailand Vittayanont, 2006
73 (Hewitt
36)
Already in contact with general
practitioner or psychiatrist
4/1655 (0.2%) NR Women 2-3 months
postpartum
Sweden Wickberg, 1996
41 (Gaynes,
24
Gibson,
25 Hewitt
36)
NR=not reported.
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RESEARCHFigure
Selection of systematic reviews and meta-analyses of diagnostic accuracy of screening tools for depression
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